506 related articles for article (PubMed ID: 29019285)
21. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
22. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
[TBL] [Abstract][Full Text] [Related]
23. The relationship between functional promoter -94 ins/del ATTG polymorphism in NF-κ B1 gene and the risk of urinary cancer.
Li X; Gao Y; Zhou H; Xu W; Li P; Zhou J; Xu T; Yu B; Xu Z; Zou Q; Yin C; Cai H; Shen W
Cancer Biomark; 2016; 16(1):11-7. PubMed ID: 26484607
[TBL] [Abstract][Full Text] [Related]
24. Genetic variations in influx transporter gene
Makhtar SM; Husin A; Baba AA; Ankathil R
J Genet; 2018 Sep; 97(4):835-842. PubMed ID: 30262695
[TBL] [Abstract][Full Text] [Related]
25. Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.
Uchida T; Kitaura J; Nakahara F; Togami K; Inoue D; Maehara A; Nishimura K; Kawabata KC; Doki N; Kakihana K; Yoshioka K; Izawa K; Oki T; Sada A; Harada Y; Ohashi K; Katayama Y; Matsui T; Harada H; Kitamura T
Exp Hematol; 2014 May; 42(5):369-379.e3. PubMed ID: 24486648
[TBL] [Abstract][Full Text] [Related]
26. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
Rostami G; Hamid M; Jalaeikhoo H
Gene; 2017 Sep; 627():202-206. PubMed ID: 28627443
[TBL] [Abstract][Full Text] [Related]
27. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
[TBL] [Abstract][Full Text] [Related]
28. Glutathione S-transferase gene polymorphic sequence variations: Association with risk and response to Imatinib among Chronic Myeloid Leukemia patients of Kashmir.
Baba SM; Shah ZA; Pandith AA; Geelani SA; Mir MM; Bhat JR; Gul A; Bhat GM
Int J Lab Hematol; 2021 Oct; 43(5):1000-1008. PubMed ID: 33470551
[TBL] [Abstract][Full Text] [Related]
29. The functional -94 insertion/deletion ATTG polymorphism in the promoter region of NFKB1 gene increases the risk of sporadic colorectal cancer.
Mohd Suzairi MS; Tan SC; Ahmad Aizat AA; Mohd Aminudin M; Siti Nurfatimah MS; Andee ZD; Ankathil R
Cancer Epidemiol; 2013 Oct; 37(5):634-8. PubMed ID: 23806437
[TBL] [Abstract][Full Text] [Related]
30. The functional 4-bp insertion/deletion ATTG polymorphism in the promoter region of NF-KB1 reduces the risk of BC.
Eskandari-Nasab E; Hashemi M; Ebrahimi M; Amininia S
Cancer Biomark; 2016; 16(1):109-15. PubMed ID: 26835711
[TBL] [Abstract][Full Text] [Related]
31. The genetic polymorphism and expression profiles of NLRP3 inflammasome in patients with chronic myeloid leukemia.
Zhang A; Yu J; Yan S; Zhao X; Chen C; Zhou Y; Zhao X; Hua M; Wang R; Zhang C; Zhong C; He N; Ji C; Ma D
Hum Immunol; 2018 Jan; 79(1):57-62. PubMed ID: 29097263
[TBL] [Abstract][Full Text] [Related]
32. Association of the GSTP1 gene (Ile105Val) polymorphism with chronic myeloid leukemia.
Sailaja K; Surekha D; Rao DN; Rao DR; Vishnupriya S
Asian Pac J Cancer Prev; 2010; 11(2):461-4. PubMed ID: 20843134
[TBL] [Abstract][Full Text] [Related]
33. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
[TBL] [Abstract][Full Text] [Related]
34. Imatinib mesylate induced erythroderma: A rare case series.
Kumar S; Mahajan BB; Kaur S; Banipal RP; Singh A
J Cancer Res Ther; 2015; 11(4):993-6. PubMed ID: 26881566
[TBL] [Abstract][Full Text] [Related]
35. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
Gambacorti-Passerini C; Antolini L; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D'Emilio A; Stagno F; le Coutre P; Hurtado-Monroy R; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Puttini M; Jang E; Reiffers J; Piazza R; Valsecchi MG; Kim DW
J Natl Cancer Inst; 2011 Apr; 103(7):553-61. PubMed ID: 21422402
[TBL] [Abstract][Full Text] [Related]
36. Lack of association between functional polymorphism of DNA repair genes (XRCC1, XPD) and clinical response in Indian chronic myeloid leukemia patients.
Dhangar S; Shanbhag V; Shanmukhaiah C; Vundinti BR
Mol Biol Rep; 2019 Oct; 46(5):4997-5003. PubMed ID: 31286393
[TBL] [Abstract][Full Text] [Related]
37. Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients.
Mohammadi F; Rostami G; Hamid M; Shafiei M; Azizi M; Bahmani H
Leuk Res; 2023 Mar; 126():107021. PubMed ID: 36696828
[TBL] [Abstract][Full Text] [Related]
38. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
39. Arginine homozygosity in codon 72 of p53 correlates with failure to imatinib response in chronic myeloid leukemia.
Camelo-Santos J; do Prado Barbosa A; de Paula Silveira-Lacerda E; Guillo LA
Biomed Pharmacother; 2013 Mar; 67(2):103-7. PubMed ID: 23433851
[TBL] [Abstract][Full Text] [Related]
40. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
